MLTX Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -2841.85%. MoonLake Immunotherapeutics's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.

MoonLake Immunotherapeutics has a consensus price target of --, signalling upside risk potential of 41.7%. On the other hand Addex Therapeutics has an analysts' consensus of -- which suggests that it could grow by 279.75%. Given that Addex Therapeutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe Addex Therapeutics is more attractive than MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. MoonLake Immunotherapeutics's net income of -$35.4M is lower than Addex Therapeutics's net income of -$1.8M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 14.60x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of --. MoonLake Immunotherapeutics's return on equity of -- beat CRISPR Therapeutics AG's return on equity of --.

MoonLake Immunotherapeutics has a consensus price target of --, signalling upside risk potential of 41.7%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.75 which suggests that it could grow by 100.76%. Given that CRISPR Therapeutics AG has higher upside potential than MoonLake Immunotherapeutics, analysts believe CRISPR Therapeutics AG is more attractive than MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.621, suggesting its more volatile than the S&P 500 by 62.069%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of --. MoonLake Immunotherapeutics's net income of -$35.4M is higher than CRISPR Therapeutics AG's net income of -$85.9M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of --. MoonLake Immunotherapeutics's return on equity of -- beat NLS Pharmaceutics's return on equity of --.

MoonLake Immunotherapeutics has a consensus price target of --, signalling upside risk potential of 41.7%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 12400.65%. Given that NLS Pharmaceutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe NLS Pharmaceutics is more attractive than MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. MoonLake Immunotherapeutics's net income of -$35.4M is higher than NLS Pharmaceutics's net income of --. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of 24.21%. MoonLake Immunotherapeutics's return on equity of -- beat Novartis AG's return on equity of 41.89%.

MoonLake Immunotherapeutics has a consensus price target of --, signalling upside risk potential of 41.7%. On the other hand Novartis AG has an analysts' consensus of -- which suggests that it could grow by 17.42%. Given that MoonLake Immunotherapeutics has higher upside potential than Novartis AG, analysts believe MoonLake Immunotherapeutics is more attractive than Novartis AG.

MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.557, suggesting its less volatile than the S&P 500 by 44.326%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.85% to investors and pays a quarterly dividend of $3.74 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Novartis AG pays out 48.86% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.2B. MoonLake Immunotherapeutics's net income of -$35.4M is lower than Novartis AG's net income of $3.2B. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Novartis AG's PE ratio is 11.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 3.99x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.